39 results about "Programmed cell death 1" patented technology

An anti-CTLA4 (cytotoxic T lymphocyte associated antigen 4) and anti-PD-1 (programmed cell death 1) bifunctional antibody. a pharmaceutical composition thereof and use thereof. Particularly, the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises a first protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically, relieve immunosuppression of CTLA4 and PD-1 on an organism specifically, activate T lymphocytes, and thus has good application prospects.

The present application provides antibodies including antigen binding fragment thereof that specifically recognizing programmed cell death 1 ligand 1 (PD-L1). Also provided are methods of making and using these antibodies.

The present disclosure generally relates to binding agents capable of targeting tumor cells and / or immune cells and their use to treat cancer. The binding agents of the present disclosure comprise one or more antigen-binding domains of a single-domain antibody capable of binding to cluster of differentiation 36 (CD36), programmed cell death protein 1 (PD-1), and / or cluster of differentiation 47 (CD47). The binding agents of the present disclosure may be monospecific or multispecific and may be in monomeric or multimeric form.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

Provided is the use of a genetically engineered phage expressing a first peptide targeting a Programmed Cell Death protein 1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) and a second peptide targeting a cancer-related antigen for enhanced efficacy in cancer treatment. Thus, provided are methods for improved anti-cancer therapy, especially in the treatment of solid tumors, by using a recombinant phage that is capable of specifically targeting the PD-1 / PD-L1 pathway and specifically targeting a cancer antigen, as well as compositions and kits useful for such treatment methods.

The present disclosure generally relates to binding agents that are capable of targeting tumor cells and immune cells. The binding agents of the present disclosure are multispecific and comprise antigen binding domains that are capable of binding to Dopamine Receptor D2 (DR2), to Programmed Cell Death Protein 1 (PD-1) and / or to Cluster of Differentiation 47 (CD47). The multispecific binding agents of the present disclosure may be used to treat subjects in need thereof.

To provide engineered PD-1 antibodies and uses thereof.SOLUTION: In some aspects, provided herein are antibodies that bind to PD-1. Antibodies provided herein, in some cases, agonize PD-1 signaling. Antibodies provided herein, in some cases, have modified Fc region. In other aspects, provided herein are compositions, methods of use, methods of making, and kits relating to antibodies that bind to PD-1. In some aspects, provided herein are methods of suppressing immune cells expressing programmed cell death 1 (PD-1), the methods comprising contacting the immune cells with an antibody that specifically binds to PD-1 and enhances an interaction between PD-1 and PD-L1 on a surface of the immune cells.SELECTED DRAWING: None

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

The present invention relates to novel anti-PD-1 (Planned Cell Death 1) antibodies and antigen binding fragments thereof for use in therapeutic and diagnostic methods, and compositions using the same.

Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed.

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

The present invention provides a means or the like capable of temporarily inhibiting expression of PD-1 or CTLA-4 protein. The present invention relates to an antisense oligonucleotide or the like capable of hybridizing with a nucleic acid sequence of an mRNA precursor and / or mature mRNA of Programmed Cell Death 1 (PD-1) protein or Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) protein and suppressing or inhibiting the expression of PD-1 protein or CTLA-4 protein.

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I). The present invention also relates to the use of the compounds of formula (I) to inhibit the programmed cell death 1 (PD1) signaling pathway and / or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Provided herein are binding molecules that bind to programmed cell death protein 1 (PD-1). Such binding molecules block the interaction between PD-1 and programmed death-ligand 1 and 2 (PD-L1 and PD-L2). Also provided herein are methods of using such binding molecules for preventing and treating cancer.

The present disclosure generally relates to binding agents that are capable of targeting tumor cells and / or immune cells and their use for treating cancer. The binding agents of the present disclosure comprise one or more antigen binding domains of single domain antibodies which are capable of binding to Cluster of Differentiation 36 (CD36), to Programmed Cell Death protein 1 (PD-1) and / or to Cluster of Differentiation 47 (CD47). The binding agents of the present disclosure are monospecific or multispecific and may be in the form of monomers or multimers.

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-Li on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

The present disclosure relates to genetically modified T cells or chimeric antigen receptor (CAR) T cells, comprising genetic modifications that inhibit or inactivate the expression of prolyl 4 hydroxylase subunit alpha 1 (P4HA1) and / or programmed cell death 1 (PD1) in the T cells or CAR T cells. The present disclosure also relates to methods of treating cancer comprising administration of the modified T cells or CAR T cells as disclosed herein; or administration of P4HA1 inhibitors and / or PD1 / PD-1L inhibitors.

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets programmed cell death protein 1 (PD-1). The disclosure also provides a method of preventing and / or treating disease, such as cancer, in a subject using the composition of the invention.

Described herein are bicyclic peptides which are high affinity binders of programmed cell death 1 ligand 1 (PD-L1). Also provided are drug conjugates comprising the peptides described herein conjugated to one or more effector and / or functional groups. Also provided are pharmaceutical compositions comprising the peptides and drug conjugates described herein, and methods of using the peptide ligands and drug conjugates described herein for treating diseases mediated by PD-L1.

The present invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

The disclosure provide means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and / or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and / or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and / or TIM-3 mediated activity in said cell. The invention also provides antibodies or variant thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.

To provide a combination therapy using a PD1-LAG3 bispecific antibody and a CD20 T cell activating bispecific antibody, use of the combination therapy for cancer treatment, and methods for using combination therapies.SOLUTION: Provided is an anti-CD20 / anti-CD3 bispecific antibody for use in the treatment of CD20-expressing cancer, where the anti-CD20 / anti-CD3 bispecific antibody is used in combination with an anti-PD1 / anti-LAG3 bispecific antibody, where the anti-PD1 / anti-LAG3 bispecific antibody comprises a first antigen binding domain that specifically binds to a programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to lymphocyte activating gene 3 (LAG3), where the first antigen binding domain that specifically binds to PD1 comprises a VH domain comprising a specific amino acid sequence and a VL domain comprising a specific amino acid sequence.SELECTED DRAWING: Figure 4

Provided herein are antibody molecules that specifically bind to Programmed Cell Death Protein 1 (PD1) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), related nucleic acid molecules, vectors, and host cells. Also provided herein are medical uses of such antibody molecules.

The present disclosure provides a method for treating, reducing the severity of, or inhibiting the growth of MUC16-expressing cancer (e.g., ovarian cancer or endometrial cancer). In certain embodiments, the method of the present disclosure comprises the step of administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to a programmed cell death 1 (PD-1) receptor, or a bispecific antibody or antigen-binding fragment thereof that specifically binds to mucin 16 (MUC16) and CD28 in combination with a bispecific antibody or antigen-binding fragment thereof that specifically binds to MUC16 and CD3, to a subject in need thereof.

The present disclosure relates to antibodies and anti-gen-binding fragments that bind specifically to the human programmed cell death protein 1 (PD-1) and methods for treating cancer or other diseases with said antibodies and antigen-binding fragments.

Provided are novel monoclonal antibodies or antibody fragments against protein programmed cell death 1 (PD-1). The antibodies or antibody fragments disclosed can block the binding of the PD- L1 ligand to PD-1 and provide potent agents for the treatment of cancers via the modulation of human immune function. Also provided are novel multispecific antibodies directed against PD-1 and cytotoxic T-lymphocyte-associated protein 4 CTLA-4.

Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.

Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and Vascular endothelial growth factor receptor 2 (VEGFR2), related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.